Aurinia Pharmaceuticals Inc (AUPH)
8.93
+0.16
(+1.82%)
USD |
NASDAQ |
Nov 22, 12:39
Aurinia Pharmaceuticals Enterprise Value: 906.94M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 906.94M |
| November 20, 2024 | 831.05M |
| November 19, 2024 | 815.30M |
| November 18, 2024 | 798.12M |
| November 15, 2024 | 813.87M |
| November 14, 2024 | 843.94M |
| November 13, 2024 | 836.78M |
| November 12, 2024 | 851.10M |
| November 11, 2024 | 866.85M |
| November 08, 2024 | 842.50M |
| November 07, 2024 | 845.37M |
| November 06, 2024 | 727.96M |
| November 05, 2024 | 698.81M |
| November 04, 2024 | 683.07M |
| November 01, 2024 | 698.81M |
| October 31, 2024 | 683.07M |
| October 30, 2024 | 704.54M |
| October 29, 2024 | 723.14M |
| October 28, 2024 | 687.36M |
| October 25, 2024 | 660.17M |
| October 24, 2024 | 658.74M |
| October 23, 2024 | 651.58M |
| October 22, 2024 | 663.03M |
| October 21, 2024 | 677.34M |
| October 18, 2024 | 657.31M |
| Date | Value |
|---|---|
| October 17, 2024 | 678.78M |
| October 16, 2024 | 678.78M |
| October 15, 2024 | 681.64M |
| October 14, 2024 | 670.19M |
| October 11, 2024 | 664.46M |
| October 10, 2024 | 650.15M |
| October 09, 2024 | 617.24M |
| October 08, 2024 | 627.26M |
| October 07, 2024 | 630.12M |
| October 04, 2024 | 670.19M |
| October 03, 2024 | 655.88M |
| October 02, 2024 | 670.19M |
| October 01, 2024 | 690.22M |
| September 30, 2024 | 700.24M |
| September 27, 2024 | 710.50M |
| September 26, 2024 | 693.34M |
| September 25, 2024 | 699.06M |
| September 24, 2024 | 673.32M |
| September 23, 2024 | 667.60M |
| September 20, 2024 | 699.06M |
| September 19, 2024 | 699.06M |
| September 18, 2024 | 681.90M |
| September 17, 2024 | 690.48M |
| September 16, 2024 | 689.05M |
| September 13, 2024 | 674.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
207.43M
Minimum
Dec 27 2022
4.000B
Maximum
Oct 29 2021
1.202B
Average
1.176B
Median
Mar 30 2023
Enterprise Value Benchmarks
| Edesa Biotech Inc | 4.811M |
| Lexaria Bioscience Corp | 25.27M |
| Xenon Pharmaceuticals Inc | 2.380B |
| ESSA Pharma Inc | -52.60M |
| ImmunoPrecise Antibodies Ltd | 8.777M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 14.35M |
| Revenue (Quarterly) | 67.77M |
| Total Expenses (Quarterly) | 56.02M |
| EPS Diluted (Quarterly) | 0.10 |
| Gross Profit Margin (Quarterly) | 91.10% |
| Profit Margin (Quarterly) | 21.17% |
| Earnings Yield | -1.57% |
| Normalized Earnings Yield | -1.091 |